NCT01003106View on ClinicalTrials.gov

Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Retinal Vein Occlusion
Interventions
DRUG

Ranibizumab 0.5mg (monthly)

Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone

DRUG

Ranibizumab 2.0mg (monthly)

DRUG

Pro re nata (prn) ranibizumab

PROCEDURE

Pro re nata (prn) Laser photocoagulation

Trial Locations (1)

21287

Wilmer Eye Institute at Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Peter A Campochiaro, MD

OTHER